March 2026 CLL Bloodline
March 1, 2026
March 2026 CLL Bloodline: The CLL Society Bloodline will teach the BASICS needed to understand CLL.
March 2026 CLL Bloodline: The CLL Society Bloodline will teach the BASICS needed to understand CLL.
Half of patients with Richter transformation responded to treatment with epcoritamab, and outcomes were even better when it was used as a first-line therapy.
Rocbrutinib appears to be effective in CLL patients with prior exposure to covalent and noncovalent BTKi, and it is generally well-tolerated.
In a phase 1 trial, BTK degrader bexobrutideg produced very good response rates in heavily pretreated patients with CLL / SLL and was generally well-tolerated.
CLL patients often have suboptimal COVID-19 vaccine responses and worse outcomes. GEO-CM04S1, a new type of vaccine, results in stronger T cell immunity.
People with CLL deserve accurate diagnosis, holistic care, and a voice in decision-making. This charter reflects input from patients, advocates, and experts.
People with CLL benefit from exercise, likely improving quality of life, yet they are rarely “prescribed” it and are less active than their peers.
Access important medications in the CLL Society Clinician Medicine Cabinet. Download key resources and order a Welcome Kit.
Discover CLL Society Clinician Resource Library CME offerings to improve care approaches for CLL and SLL patients.